2-mg Intravitreous Aflibercept Injection
Phase 2/3Completed 0 watching 0 views this week📈 Rising
64
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Proliferative Diabetic Retinopathy
Conditions
Proliferative Diabetic Retinopathy, Vitreous Hemorrhage
Trial Timeline
Nov 1, 2016 → Jan 1, 2020
NCT ID
NCT02858076About 2-mg Intravitreous Aflibercept Injection
2-mg Intravitreous Aflibercept Injection is a phase 2/3 stage product being developed by Regeneron Pharmaceuticals for Proliferative Diabetic Retinopathy. The current trial status is completed. This product is registered under clinical trial identifier NCT02858076. Target conditions include Proliferative Diabetic Retinopathy, Vitreous Hemorrhage.
Hype Score Breakdown
Clinical
22
Activity
15
Company
9
Novelty
7
Community
8
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT02858076 | Phase 2/3 | Completed |
Competing Products
20 competing products in Proliferative Diabetic Retinopathy
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| LY2784544 | Eli Lilly | Phase 1 | 33 |
| LY2784544 | Eli Lilly | Phase 1 | 33 |
| Navitoclax + Ruxolitinib + Celecoxib | AbbVie | Phase 1 | 33 |
| Epcoritamab | AbbVie | Phase 1 | 33 |
| Brolucizumab 6 mg | Novartis | Phase 3 | 77 |
| CANAKINUMAB (ILARIS®) | Novartis | Phase 1 | 33 |
| Lucentis | Novartis | Approved | 85 |
| Ranibizumab | Novartis | Approved | 85 |
| Octreotide, 30 mg i.m. LAR formulation | Novartis | Phase 3 | 77 |
| Ranibizumab 0.5 mg | Novartis | Phase 2 | 52 |
| AUY922 | Novartis | Phase 2 | 52 |
| Lucentis | Roche | Pre-clinical | 23 |
| Macugen (pegaptanib) + Macugen (Pegaptanib) | Pfizer | Pre-clinical | 22 |
| Macugen ® (pegaptanib sodium) | Pfizer | Approved | 84 |
| Pacritinib + Decitabine + Decitabine and Cedazuridine + Azacitidine | Swedish Orphan Biovitrum | Phase 2 | 51 |
| Fedratinib Pill | Bristol Myers Squibb | Phase 2 | 51 |
| VAC85135 + Ipilimumab | Bristol Myers Squibb | Phase 1 | 32 |
| Fedratinib Pill | Bristol Myers Squibb | Phase 1 | 32 |
| Fedratinib Oral Capsule 300 mg + Decitabine 20 mg/m2 + Fedratinib Oral Capsule 400 mg | Bristol Myers Squibb | Phase 1 | 32 |
| Aflibercept | Regeneron Pharmaceuticals | Phase 2 | 51 |